Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18641960 | 0.89 | ALDH1A1 (0.41) | PLA2G4AEPHX2PLA2G2AADRA1APRMT1 | |
| SCHEMBL18641935 | 0.89 | ALDH1A1 (0.41) | PLA2G4AEPHX2PLA2G2AADRA1APRMT1 | |
| SCHEMBL18666797 | 0.87 | PRMT1 (0.42) | PLA2G4AEPHX2ADRA1APRMT1MEN1 | |
| SCHEMBL23030243 | 0.83 | TSHR (0.45) | EPHX2ALDH1A1 | |
| SCHEMBL22852612 | 0.79 | PLA2G4A (0.44) | PLA2G4AEPHX2PLA2G2AADRA1APRMT1 | |
| SCHEMBL22188140 | 0.78 | EPHX2 (0.40) | EPHX2MEN1KMT2ATDP1 | |
| SCHEMBL9726453 | 0.75 | PRMT1 (0.48) | PLA2G4AEPHX2ADRA1APRMT1MEN1 | |
| SCHEMBL28254961 | 0.72 | PLA2G4A (0.55) | PLA2G4AEPHX2PLA2G2AADRA1APRMT1 | |
| SCHEMBL20657261 | 0.72 | KMT2A (0.49) | PLA2G4AEPHX2ADRA1APRMT1MEN1 | |
| SCHEMBL28459307 | 0.72 | KMT2A (0.49) | PLA2G4AEPHX2ADRA1APRMT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | disclosed |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-20220378951-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-20210353777-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20210346523-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| US-20210346523-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20210052747-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20210052747-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-3411074-A2 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | Suzhou M-conj Biotech Co., Ltd. (CN) | 2018-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052747-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-20210353777-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | PLA2G4A 2155/4885EPHX2 4164/4885PLA2G2A 1942/4885 |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | PLA2G4A 2155/4885EPHX2 4164/4885PLA2G2A 1942/4885 |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, TEK, BTN3A1 | PLA2G4A 3089/4885EPHX2 3888/4885PLA2G2A 2805/4885 |
| US-20220378951-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
| US-20210346523-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | PLA2G4A 3769/4885EPHX2 791/4885PLA2G2A 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.